Enterprise Value
559.8M
Cash
347.6M
Avg Qtr Burn
-21.49M
Short % of Float
11.96%
Insider Ownership
25.22%
Institutional Own.
48.71%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TCER® IMA402 (PRAME) Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
ACTengine IMA203 (PRAME) Details Cancer, Solid tumor/s | Phase 1b Data readout | |
TCER® IMA401 (MAGEA4/8) Details Solid tumor/s, Cancer | Phase 1 Update | |
ACTengine IMA201 Details Solid tumor/s, Cancer | Failed Discontinued | |
ACTengine IMA202 Details Cancer, Solid tumor/s | Failed Discontinued |